TrialArthritis & rheumatology (Hoboken, N.J.)2021

Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.

Hermine I Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.